|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.660 USD | -0.21% |
|
-.--% | +3.10% |
| Apr. 15 | Evotec Taps CureVac Executive as COO | MT |
| Jan. 06 | CureVac ends coverage after BioNTech acquisition | ![]() |
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
Profitability | |||||||
Return on Assets | -10.17 | -49.31 | -14.02 | -20.6 | 16.48 | ||
Return on Total Capital | -20.79 | -88.71 | -21.89 | -29.95 | 20.26 | ||
Return On Equity % | -38.63 | -58.82 | -40.77 | -49.55 | 26.73 | ||
Return on Common Equity | -38.63 | -58.82 | -40.77 | -49.55 | 26.73 | ||
Margin Analysis | |||||||
Gross Profit Margin % | 71.1 | -131.16 | -135.79 | -116.17 | 80.26 | ||
SG&A Margin | 111.18 | 99.3 | 158.81 | 178.09 | 13.89 | ||
EBITDA Margin % | -261.36 | -1.01K | -310.89 | -474.25 | 41.59 | ||
EBITA Margin % | -269.88 | -1.02K | -330.75 | -497.61 | 39.68 | ||
EBIT Margin % | -273.27 | -1.02K | -335.72 | -505.49 | 39.2 | ||
Income From Continuing Operations Margin % | -264.21 | -399.76 | -369.37 | -483.96 | 30.3 | ||
Net Income Margin % | -264.21 | -399.76 | -369.37 | -483.96 | 30.3 | ||
Net Avail. For Common Margin % | -264.21 | -399.76 | -369.37 | -483.96 | 30.3 | ||
Normalized Net Income Margin | -196.42 | -639.26 | -209.55 | -299.38 | 26.04 | ||
Levered Free Cash Flow Margin | 118.52 | -692.66 | -544.01 | -281.85 | 9.81 | ||
Unlevered Free Cash Flow Margin | 146.78 | -686.39 | -540.58 | -281.85 | 9.81 | ||
Asset Turnover | |||||||
Asset Turnover | 0.06 | 0.08 | 0.07 | 0.07 | 0.67 | ||
Fixed Assets Turnover | 0.6 | 0.68 | 0.31 | 0.21 | 2.05 | ||
Receivables Turnover (Average Receivables) | 5.15 | 10.13 | 4.9 | 4.12 | 31.55 | ||
Inventory Turnover (Average Inventory) | 1.36 | 6.74 | 3.97 | 4.76 | 8.34 | ||
Short Term Liquidity | |||||||
Current Ratio | 5.61 | 2.63 | 3.74 | 2.57 | 7.28 | ||
Quick Ratio | 5.39 | 2.43 | 3.44 | 2.38 | 7.11 | ||
Operating Cash Flow to Current Liabilities | 2.11 | -2.05 | -1.83 | -1.44 | 1.41 | ||
Days Sales Outstanding (Average Receivables) | 71.05 | 36.02 | 74.46 | 88.56 | 11.6 | ||
Days Outstanding Inventory (Average Inventory) | 268.55 | 54.19 | 92.01 | 76.62 | 43.9 | ||
Average Days Payable Outstanding | 187.03 | 91.27 | 274.2 | - | 146.87 | ||
Cash Conversion Cycle (Average Days) | 152.57 | -1.07 | -107.73 | - | -91.36 | ||
Long Term Solvency | |||||||
Total Debt/Equity | 7.77 | 4.2 | 7.89 | 8.09 | 5.59 | ||
Total Debt / Total Capital | 7.21 | 4.03 | 7.31 | 7.48 | 5.3 | ||
LT Debt/Equity | 7.32 | 3.69 | 6.96 | 7.12 | 4.83 | ||
Long-Term Debt / Total Capital | 6.79 | 3.54 | 6.45 | 6.59 | 4.57 | ||
Total Liabilities / Total Assets | 52.93 | 40.56 | 38.03 | 34.42 | 13.23 | ||
EBIT / Interest Expense | -6.04 | -101.87 | -61.06 | - | - | ||
EBITDA / Interest Expense | -5.61 | -100.57 | -55.18 | - | - | ||
(EBITDA - Capex) / Interest Expense | -7.25 | -112.58 | -78.92 | - | - | ||
Total Debt / EBITDA | -0.45 | -0.03 | -0.21 | -0.17 | 0.17 | ||
Net Debt / EBITDA | 10.24 | 0.75 | 2.22 | 1.45 | -1.94 | ||
Total Debt / (EBITDA - Capex) | -0.34 | -0.02 | -0.14 | -0.14 | 0.18 | ||
Net Debt / (EBITDA - Capex) | 7.92 | 0.67 | 1.55 | 1.2 | -2.08 | ||
Growth Over Prior Year | |||||||
Total Revenues, 1 Yr. Growth % | 180.61 | 110.74 | -34.54 | -20.26 | 895.54 | ||
Gross Profit, 1 Yr. Growth % | -434.1 | -488.78 | -18.46 | -31.78 | -787.8 | ||
EBITDA, 1 Yr. Growth % | 25.76 | 717.01 | -79.47 | 21.76 | -189.26 | ||
EBITA, 1 Yr. Growth % | 25.75 | 696.55 | -78.3 | 19.96 | -181.08 | ||
EBIT, 1 Yr. Growth % | 27.33 | 688.58 | -78.03 | 20.06 | -178.83 | ||
Earnings From Cont. Operations, 1 Yr. Growth % | 29.29 | 218.86 | -39.51 | 4.47 | -162.34 | ||
Net Income, 1 Yr. Growth % | 29.29 | 218.86 | -39.51 | 4.47 | -162.34 | ||
Normalized Net Income, 1 Yr. Growth % | 45.56 | 585.87 | -78.07 | 13.92 | -188.53 | ||
Diluted EPS Before Extra, 1 Yr. Growth % | -5.43 | 126.61 | -40.49 | -10.61 | -161.02 | ||
Accounts Receivable, 1 Yr. Growth % | -89.38 | 915.59 | -51.35 | 89.78 | -1.42 | ||
Inventory, 1 Yr. Growth % | 134.48 | 286.48 | -57.28 | 3.38 | -97.82 | ||
Net Property, Plant and Equip., 1 Yr. Growth % | 63.07 | 99.22 | 20.61 | 15.28 | -12.19 | ||
Total Assets, 1 Yr. Growth % | 1.06K | -23.36 | -25.71 | -8.39 | 1.85 | ||
Tangible Book Value, 1 Yr. Growth % | -1.55K | -3.11 | -25.84 | -2.57 | 37.43 | ||
Common Equity, 1 Yr. Growth % | -1.76K | -3.22 | -22.55 | -3.06 | 34.76 | ||
Cash From Operations, 1 Yr. Growth % | -700.72 | -240.34 | -60.96 | -6.39 | -138.02 | ||
Capital Expenditures, 1 Yr. Growth % | 225.18 | 241.94 | -29.14 | -40.56 | -72.64 | ||
Levered Free Cash Flow, 1 Yr. Growth % | -186.96 | -1.37K | -47.54 | -58.59 | -135.48 | ||
Unlevered Free Cash Flow, 1 Yr. Growth % | -209.2 | -1.11K | -47.38 | -58.43 | -135.48 | ||
Compound Annual Growth Rate Over Two Years | |||||||
Total Revenues, 2 Yr. CAGR % | 94.86 | 143.18 | 17.45 | -27.75 | 181.74 | ||
Gross Profit, 2 Yr. CAGR % | 167.03 | 257.54 | 62.43 | -25.42 | 116.61 | ||
EBITDA, 2 Yr. CAGR % | 35.22 | 226.79 | 30.49 | -50.01 | 3.99 | ||
EBITA, 2 Yr. CAGR % | 33.84 | 216.5 | 29.22 | -48.98 | -2.75 | ||
EBIT, 2 Yr. CAGR % | 34.68 | 216.88 | 30.18 | -48.64 | -3.34 | ||
Earnings From Cont. Operations, 2 Yr. CAGR % | 34.63 | 103.04 | 38.88 | -20.51 | -19.3 | ||
Net Income, 2 Yr. CAGR % | 34.63 | 103.04 | 38.88 | -20.51 | -19.3 | ||
Normalized Net Income, 2 Yr. CAGR % | 46.11 | 215.97 | 21.32 | -50.01 | -0.27 | ||
Diluted EPS Before Extra, 2 Yr. CAGR % | 15.14 | 46.39 | 16.12 | -26.98 | -26.15 | ||
Accounts Receivable, 2 Yr. CAGR % | -48.46 | 3.86 | 122.28 | -3.91 | 36.78 | ||
Inventory, 2 Yr. CAGR % | 121.9 | 201.04 | 28.49 | -33.55 | -84.98 | ||
Net Property, Plant and Equip., 2 Yr. CAGR % | 57.65 | 80.24 | 55.01 | 17.91 | 0.61 | ||
Total Assets, 2 Yr. CAGR % | 246.81 | 197.78 | -24.55 | -17.5 | -3.41 | ||
Tangible Book Value, 2 Yr. CAGR % | 417.02 | 274.48 | -15.23 | -15 | 15.71 | ||
Common Equity, 2 Yr. CAGR % | 370.87 | 301.06 | -13.42 | -13.35 | 14.3 | ||
Cash From Operations, 2 Yr. CAGR % | 165.5 | 190.35 | -25.99 | -39.55 | -40.34 | ||
Capital Expenditures, 2 Yr. CAGR % | 96.53 | 233.45 | 55.66 | -35.1 | -59.67 | ||
Levered Free Cash Flow, 2 Yr. CAGR % | - | 227.27 | 155.12 | -53.37 | -62.06 | ||
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | 228.04 | 127.91 | -53.23 | -61.98 | ||
Compound Annual Growth Rate Over Three Years | |||||||
Total Revenues, 3 Yr. CAGR % | - | 100.01 | 57.02 | 3.23 | 73.21 | ||
Gross Profit, 3 Yr. CAGR % | - | 202.65 | 105.38 | 21.64 | 56.4 | ||
EBITDA, 3 Yr. CAGR % | - | 146.29 | 28.96 | 27.47 | -39.8 | ||
EBITA, 3 Yr. CAGR % | - | 142.54 | 28.59 | 26.06 | -40.88 | ||
EBIT, 3 Yr. CAGR % | - | 142.74 | 29.23 | 26.72 | -41.17 | ||
Earnings From Cont. Operations, 3 Yr. CAGR % | - | 79.46 | 35.6 | 26.3 | -26.69 | ||
Net Income, 3 Yr. CAGR % | - | 79.46 | 35.6 | 26.3 | -26.69 | ||
Normalized Net Income, 3 Yr. CAGR % | - | 144.65 | 28.91 | 18.8 | -39.97 | ||
Diluted EPS Before Extra, 3 Yr. CAGR % | - | 44.29 | 8.44 | 6.5 | -31.23 | ||
Accounts Receivable, 3 Yr. CAGR % | - | 39.22 | -19.34 | 110.87 | -3.09 | ||
Inventory, 3 Yr. CAGR % | - | 166.98 | 57.02 | 19.51 | -78.72 | ||
Net Property, Plant and Equip., 3 Yr. CAGR % | - | 70.44 | 57.65 | 40.44 | 6.88 | ||
Total Assets, 3 Yr. CAGR % | - | 109.67 | 87.46 | -19.51 | -11.5 | ||
Tangible Book Value, 3 Yr. CAGR % | - | 195.87 | 118.28 | -11.21 | -0.23 | ||
Common Equity, 3 Yr. CAGR % | - | 177.89 | 131.82 | -10.09 | 0.39 | ||
Cash From Operations, 3 Yr. CAGR % | - | 114.67 | 48.74 | -19.96 | -48.21 | ||
Capital Expenditures, 3 Yr. CAGR % | - | 136.37 | 98.99 | 12.93 | -51.34 | ||
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | 76.59 | 39.05 | -57.76 | ||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | 77.03 | 29.25 | -57.68 | ||
Compound Annual Growth Rate Over Five Years | |||||||
Total Revenues, 5 Yr. CAGR % | - | - | - | 33.1 | 98.39 | ||
Gross Profit, 5 Yr. CAGR % | - | - | - | 66.55 | 109.8 | ||
EBITDA, 5 Yr. CAGR % | - | - | - | 29.56 | 17.89 | ||
EBITA, 5 Yr. CAGR % | - | - | - | 29.44 | 15.15 | ||
EBIT, 5 Yr. CAGR % | - | - | - | 29.84 | 14.87 | ||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | 29.57 | 10.18 | ||
Net Income, 5 Yr. CAGR % | - | - | - | 29.57 | 10.18 | ||
Normalized Net Income, 5 Yr. CAGR % | - | - | - | 29.05 | 16.14 | ||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | 9.88 | -6.96 | ||
Accounts Receivable, 5 Yr. CAGR % | - | - | - | 20.03 | -0.37 | ||
Inventory, 5 Yr. CAGR % | - | - | - | 53.07 | -38.6 | ||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | 47.09 | 31.73 | ||
Total Assets, 5 Yr. CAGR % | - | - | - | 44.38 | 43.79 | ||
Tangible Book Value, 5 Yr. CAGR % | - | - | - | 79.65 | 69.34 | ||
Common Equity, 5 Yr. CAGR % | - | - | - | 74.35 | 74.7 | ||
Cash From Operations, 5 Yr. CAGR % | - | - | - | 29.3 | 3.21 | ||
Capital Expenditures, 5 Yr. CAGR % | - | - | - | 40.95 | 5.08 | ||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | -4.65 | ||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | -4.38 |
- Stock Market
- Stocks
- CVAC Stock
- Financials CureVac
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions

















